Hims Weight Loss Review
From $4 · Free consult · 4.2★ on Trustpilot · All 50 States
7,811 verified reviews
Compounded semaglutide at one of the lowest entry prices in telehealth — async-light intake fits straightforward GLP-1 candidates.
Is Hims the right fit for you?
Who it's for
- Adults with BMI 30+ (or BMI 27+ with weight-related comorbidity like type 2 diabetes, hypertension, or sleep apnea) who want low-friction access to compounded semaglutide without insurance prior-authorization workflow
- Cost-sensitive GLP-1 buyers — Hims compounded semaglutide at $199/mo is meaningfully below most mass-market telehealth weight-loss options and dramatically below cash-pay brand-name Wegovy or Ozempic ($1,000+/mo without insurance)
- Existing Hims subscribers across other verticals who want consolidated account management — bundling matters when you're managing ED, hair-loss, and weight-loss subscriptions
- Patients comfortable with the regulatory framing of compounded GLP-1s — Hims dispenses compounded semaglutide from 503A/503B partners under physician supervision, but does not offer brand-name Wegovy or Mounjaro at this price point
Who it's not for
- Anyone with personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 syndrome — these are FDA-labeled contraindications for GLP-1 medications and Hims' async intake is the wrong environment for that risk-benefit conversation
- Patients with severe gastroparesis, prior pancreatitis, or active gallbladder disease — GLP-1s slow gastric emptying and can exacerbate these conditions; a hands-on clinical evaluation is more appropriate
- Anyone wanting brand-name Wegovy, Ozempic, or Mounjaro specifically — Hims is compounded-only at this price point. The FDA shortage that historically permitted compounded semaglutide ended in early 2026, so compounded GLP-1 availability is now more restricted than during the peak shortage window
- Patients who need integrated metabolic optimization (advanced lipids, fasting insulin, leptin) alongside GLP-1 — Hims' async ED-style intake doesn't include this depth; a clinical hormone-and-metabolic clinic is the better entry
Your first 3 months with Hims
Complete the Hims weight-loss intake — weight history, BMI, medical conditions, GLP-1 contraindications (MTC family history, severe gastroparesis, prior pancreatitis), current medications, target weight, and prior weight-loss attempts. Free async consult is the platform default; most prescriptions are written within 24–72 hours.
Lab order issued for baseline metabolic markers — fasting glucose, HbA1c, lipid panel, thyroid (TSH + free T4), liver enzymes, kidney function. Local LabCorp or Quest draw site visit; results in 2–3 business days. Prescriber reviews labs and either confirms protocol or escalates if anything flags.
First compounded semaglutide shipment lands. Standard start is 0.25mg weekly subcutaneous injection — conservative entry to manage GI tolerance. First month typically produces 2–5 pounds of loss alongside appetite reduction. Side effects (nausea, mild GI upset) peak in the first 2–4 weeks then subside for most patients.
Dose titration to therapeutic range (0.5mg → 1mg → 1.7mg → 2.4mg/week depending on response and tolerance). Average loss at 6 months on therapeutic-dose semaglutide runs 10–15% of starting body weight in responders. Follow-up labs at 12 weeks then quarterly. The hard question at 6 months: how to maintain the loss — Hims continues prescribing at maintenance doses, but the regain risk on full discontinuation is the long-term consideration.
Hims vs the alternatives
[PeterMD](/online-providers/weight-loss/petermd) and Hims compete on compounded GLP-1 telehealth at similar price points (Hims $199/mo, PeterMD $200–$300/mo depending on dose tier). PeterMD's edge is multi-medication catalog: semaglutide, tirzepatide, and phentermine all available under one prescriber so you can switch medications during treatment if your first protocol underperforms. Hims is semaglutide-focused — if tirzepatide is on your radar, Hims doesn't have it at this price point. AHF rates Hims 4.0 (weight-loss) and PeterMD 4.3 (weight-loss) — gap reflects PeterMD's medication flexibility advantage. Pick Hims if compounded semaglutide at the lowest price is the priority. Pick PeterMD if you want medication-switching flexibility within one provider relationship.
[Marek Health](/online-providers/weight-loss/marek-health) brings premium-concierge GLP-1 prescribing — comprehensive metabolic panels (ApoB, fasting insulin, leptin), deeper clinical-relationship pricing ($300–$600+/mo all-in), more rigorous monitoring cadence. Hims is the volume-optimized mass-market operation at materially lower entry pricing. AHF rates Hims 4.0 and Marek 4.4 (weight-loss). Pick Hims if cost-conscious GLP-1 with appropriate baseline monitoring is enough for your case. Pick Marek if you have layered metabolic factors (insulin resistance, inflammatory markers, integrated hormone considerations) and your budget supports the comprehensive workup.
Honest Breakdown
What Works Well
- Extremely affordable ED meds starting at $4/dose
- Massive scale with 2.5M+ active subscribers
- Free online consultations included
- Publicly traded company (NYSE: HIMS) - established trust
- Available in all 50 states
- Wide range of treatments in one platform
- Discreet packaging and fast shipping
- Chewable ED options (Hard Mints) available
Watch Points
- Subscription cancellation can be difficult
- Mixed customer service reviews
- No injectable TRT yet (coming 2026)
- Uses compounded GLP-1 (not brand-name Ozempic/Wegovy)
What people actually ask about Hims
Yes — Hims operates as a publicly-traded U.S. telehealth platform with licensed physicians prescribing in each state served. Compounded semaglutide is dispensed through 503A/503B compounding pharmacy partners under physician orders. The medication is real, the prescribing process is real, and the legitimacy infrastructure (NYSE: HIMS, $2.35B revenue, public company financial disclosures) is verifiable. The watch points are platform-scale issues (async-rigor at volume, cancellation friction) and the regulatory-shifting landscape for compounded GLP-1s post-FDA-shortage-end, not the legitimacy of the basic operation.
Ready to start with Hims?
Free consultation. Independently reviewed. Board-certified physicians.
Get Free ConsultationSecure telemedicine · HIPAA compliant · Cancel anytime